Reduced IQGAP2 Promotes Bladder Cancer through Regulation of MAPK/ERK Pathway and Cytokines

GND
1286738326
Zugehörigkeit
Department of Urology, Jena University Hospital
Song, Fei;
GND
1220253227
ORCID
0000-0002-3122-239X
Zugehörigkeit
Department of Urology, Jena University Hospital
Kotolloshi, Roland;
GND
130399264
Zugehörigkeit
Section of Pathology, Department of Forensic Medicine, Jena University Hospital
Gajda, Mieczyslaw;
GND
1151924458
ORCID
0000-0001-7090-8717
Zugehörigkeit
RNA Bioinformatics and High-Throughput Analysis, Friedrich Schiller University Jena
Hölzer, Martin;
GND
115682899
ORCID
0000-0003-3084-8654
Zugehörigkeit
Department of Urology, Jena University Hospital
Grimm, Marc-Oliver;
GND
1059423553
ORCID
0000-0002-0276-3701
Zugehörigkeit
Department of Urology, Jena University Hospital, 07740 Jena, Germany
Steinbach, Daniel

The progression of non-muscle-invasive bladder cancer (NMIBC) to muscle-invasive bladder cancer (MIBC) is a major challenge in urologic oncology. However, understanding of the molecular processes remains limited. The dysregulation of IQGAP2 is becoming increasingly evident in most tumor entities, and it plays a role in multiple oncogenic pathways, so we evaluated the role of IQGAP2 in bladder cancer. IQGAP2 was downregulated in tumors compared with normal urothelium tissues and cells. IQGAP2 effectively attenuated bladder cancer cell growth independently from apoptosis. Reduced IQGAP2 promoted EMT in bladder cancer cells via activation of the MAPK/ERK pathway. In addition, IQGAP2 might influence key cellular processes, such as proliferation and metastasis, through the regulation of cytokines. In conclusion, we suggest that IQGAP2 plays a tumor-suppressing role in bladder cancer, possibly via inhibiting the MAPK/ERK pathway and reducing cytokines.

Zitieren

Zitierform:
Zitierform konnte nicht geladen werden.

Rechte

Rechteinhaber: © 2022 by the authors.

Nutzung und Vervielfältigung: